Athena Athena

X
[{"orgOrder":0,"company":"Aptamer Group","sponsor":"PinotBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Aptamer Group

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.

            Lead Product(s): FL-118-based Drug Conjugate

            Therapeutic Area: Oncology Product Name: FL-118

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: PinotBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 03, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY